BR9814142A - Organismo não humano transgênico, célula ou linha de célula do mesmo, método para produzir um mamìfero não humano com uma interrupção dirigida em um gene antagonista receptor da interleucina-1 (il-1rn), construção nocaute de antagonista receptor il-1, construção nocaute il-1rn e método para testar um agente quanto a efetividade contra uma condição inflamatória. - Google Patents

Organismo não humano transgênico, célula ou linha de célula do mesmo, método para produzir um mamìfero não humano com uma interrupção dirigida em um gene antagonista receptor da interleucina-1 (il-1rn), construção nocaute de antagonista receptor il-1, construção nocaute il-1rn e método para testar um agente quanto a efetividade contra uma condição inflamatória.

Info

Publication number
BR9814142A
BR9814142A BR9814142-2A BR9814142A BR9814142A BR 9814142 A BR9814142 A BR 9814142A BR 9814142 A BR9814142 A BR 9814142A BR 9814142 A BR9814142 A BR 9814142A
Authority
BR
Brazil
Prior art keywords
antagonist
interleukin
knockout
cell
human
Prior art date
Application number
BR9814142-2A
Other languages
English (en)
Portuguese (pt)
Inventor
Gordon W Duff
Martin Nicklin
Original Assignee
Interleukin Genetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Interleukin Genetics Inc filed Critical Interleukin Genetics Inc
Publication of BR9814142A publication Critical patent/BR9814142A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0276—Knock-out vertebrates
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/033—Rearing or breeding invertebrates; New breeds of invertebrates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0306—Animal model for genetic diseases
    • A01K2267/0325—Animal model for autoimmune diseases
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • A01K2267/0368—Animal model for inflammation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Environmental Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Plant Pathology (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Microbiology (AREA)
  • Animal Husbandry (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
BR9814142-2A 1997-11-13 1998-11-13 Organismo não humano transgênico, célula ou linha de célula do mesmo, método para produzir um mamìfero não humano com uma interrupção dirigida em um gene antagonista receptor da interleucina-1 (il-1rn), construção nocaute de antagonista receptor il-1, construção nocaute il-1rn e método para testar um agente quanto a efetividade contra uma condição inflamatória. BR9814142A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9723835.6A GB9723835D0 (en) 1997-11-13 1997-11-13 Interleukin knockout
PCT/US1998/024287 WO1999025857A2 (en) 1997-11-13 1998-11-13 Transgenic models of inflammatory disease

Publications (1)

Publication Number Publication Date
BR9814142A true BR9814142A (pt) 2000-10-03

Family

ID=10821919

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9814142-2A BR9814142A (pt) 1997-11-13 1998-11-13 Organismo não humano transgênico, célula ou linha de célula do mesmo, método para produzir um mamìfero não humano com uma interrupção dirigida em um gene antagonista receptor da interleucina-1 (il-1rn), construção nocaute de antagonista receptor il-1, construção nocaute il-1rn e método para testar um agente quanto a efetividade contra uma condição inflamatória.

Country Status (13)

Country Link
EP (1) EP1030926A2 (ja)
JP (1) JP2001523467A (ja)
KR (1) KR20010015814A (ja)
AU (1) AU1796699A (ja)
BR (1) BR9814142A (ja)
CA (1) CA2309807A1 (ja)
GB (1) GB9723835D0 (ja)
HU (1) HUP0004352A2 (ja)
IL (1) IL136013A0 (ja)
NO (1) NO20002477L (ja)
PL (1) PL340829A1 (ja)
TR (1) TR200001356T2 (ja)
WO (1) WO1999025857A2 (ja)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6437216B1 (en) 1997-11-13 2002-08-20 Interleukin Genetics Inc. Transgenic models of inflammatory disease
WO2001056606A1 (fr) * 2000-01-31 2001-08-09 Santen Pharmaceutical Co., Ltd. Remedes pour troubles ophtalmiques
KR20030067204A (ko) * 2002-02-07 2003-08-14 한국생명공학연구원 퍼록시레독신-ⅱ 유전자 결손 생쥐 및 이의 생산방법
EP1723235B1 (en) * 2004-02-12 2012-06-27 The Walter And Eliza Hall Institute Of Medical Research Modified cells that co-express blimp1 and a reporter molecule and methods of using the same
JP2009183176A (ja) * 2008-02-05 2009-08-20 Univ Of Tokyo Ｉｌ−１タイプｉｉレセプター遺伝子の欠損変異体マウス
JP5186637B2 (ja) * 2009-07-30 2013-04-17 国立大学法人富山大学 トランスジェニック非ヒト哺乳動物およびその利用
WO2019235839A1 (ko) * 2018-06-05 2019-12-12 사회복지법인 삼성생명공익재단 그레이브스 안병증 표현형 동물 모델, 그의 제조방법 및 그레이브스 안병증 치료물질 스크리닝 방법

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1269989B (it) * 1994-09-21 1997-04-16 Dompe Spa Antagonisti recettoriali di il-1 ad aumentata attivita' inibitoria
EP0787179A4 (en) * 1994-10-20 1999-05-19 Merck & Co Inc TRANSGENIC ANIMALS WITH INTERLEUKIN-1-g (b) DEFICIENCY
US6210877B1 (en) * 1997-03-10 2001-04-03 Interleukin Genetics, Inc. Prediction of coronary artery disease

Also Published As

Publication number Publication date
TR200001356T2 (tr) 2000-08-21
AU1796699A (en) 1999-06-07
NO20002477L (no) 2000-07-12
NO20002477D0 (no) 2000-05-12
HUP0004352A2 (en) 2001-03-28
KR20010015814A (ko) 2001-02-26
PL340829A1 (en) 2001-02-26
WO1999025857A3 (en) 1999-07-15
JP2001523467A (ja) 2001-11-27
CA2309807A1 (en) 1999-05-27
EP1030926A2 (en) 2000-08-30
WO1999025857A2 (en) 1999-05-27
IL136013A0 (en) 2001-05-20
GB9723835D0 (en) 1998-01-07

Similar Documents

Publication Publication Date Title
Lovatt et al. Neuronal adenosine release, and not astrocytic ATP release, mediates feedback inhibition of excitatory activity
Boehler et al. Poly (ADP-ribose) polymerase 3 (PARP3), a newcomer in cellular response to DNA damage and mitotic progression
Tueting et al. The phenotypic characteristics of heterozygous reeler mouse
Suárez-Álvarez et al. Epigenetic modulation of the immune function: a potential target for tolerance
Fujioka et al. Proinflammatory cytokines expression in noise‐induced damaged cochlea
Sugiura et al. Leukaemia inhibitory factor is required for normal inflammatory responses to injury in the peripheral and central nervous systems in vivo and is chemotactic for macrophages in vitro
Kozel et al. Deficiency in plasma membrane calcium ATPase isoform 2 increases susceptibility to noise-induced hearing loss in mice
Kiripolsky et al. Innate immunity in Sjögren's syndrome
Ribeiro et al. A potent systemically active N-acylethanolamine acid amidase inhibitor that suppresses inflammation and human macrophage activation
Fujihara et al. Glutamate decarboxylase 67 deficiency in a subset of GABAergic neurons induces schizophrenia-related phenotypes
Bikson et al. Depolarization block of neurons during maintenance of electrographic seizures
Garrett-Sinha et al. PU. 1 and Spi-B are required for normal B cell receptor–mediated signal transduction
Sha et al. Overexpression of copper/zinc-superoxide dismutase protects from kanamycin-induced hearing loss
Bogdanik et al. Systemic, postsymptomatic antisense oligonucleotide rescues motor unit maturation delay in a new mouse model for type II/III spinal muscular atrophy
Duffy et al. Myelin-derived ephrinB3 restricts axonal regeneration and recovery after adult CNS injury
Geiman et al. Lsh, an SNF2/helicase family member, is required for proliferation of mature T lymphocytes
Draxler et al. VGluT3+ primary afferents play distinct roles in mechanical and cold hypersensitivity depending on pain etiology
Peloquin et al. Functional analysis of Cav3. 2 T‐type calcium channel mutations linked to childhood absence epilepsy
Dai et al. Amelioration of antigen-induced arthritis in rats by transfer of extracellular superoxide dismutase and catalase genes
Sun et al. Loss of HDAC11 ameliorates clinical symptoms in a multiple sclerosis mouse model
Syberg et al. Genetic background strongly influences the bone phenotype of P2X7 receptor knockout mice
BR9814142A (pt) Organismo não humano transgênico, célula ou linha de célula do mesmo, método para produzir um mamìfero não humano com uma interrupção dirigida em um gene antagonista receptor da interleucina-1 (il-1rn), construção nocaute de antagonista receptor il-1, construção nocaute il-1rn e método para testar um agente quanto a efetividade contra uma condição inflamatória.
Redlingshöfer et al. Clathrin light chain diversity regulates membrane deformation in vitro and synaptic vesicle formation in vivo
Bedard et al. Sterile activation of invariant natural killer T cells by ER-stressed antigen-presenting cells
Zhang et al. Repressor element 1–silencing transcription factor drives the development of chronic pain states

Legal Events

Date Code Title Description
FA10 Dismissal: dismissal - article 33 of industrial property law
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]